We are live on ! Find out more
ED

Exane Derivatives Portfolio holdings

AUM $174M
1-Year Est. Return 7.84%
This Fund
S&P 500
This Quarter Est. Return
+7.67%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
AUM
$441M
AUM Growth
+$91.2M
Cap. Flow
+$74.5M
Cap. Flow %
16.9%
Top 10 Hldgs %
24.04%
Holding
1,099
New
222
Increased
266
Reduced
262
Closed
55

Top Buys

Rank Stock Value
1
UBS icon
UBS Group
UBS
+$15.4M
2
STLA icon
Stellantis
STLA
+$9.9M
3
ALC icon
Alcon
ALC
+$7.77M
4
AMZN icon
Amazon
AMZN
+$6.64M
5
RACE icon
Ferrari
RACE
+$5.26M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 15.26%
2 Technology 13.6%
3 Financials 12.86%
4 Healthcare 10.91%
5 Industrials 10.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NOC icon
451
Northrop Grumman
NOC
$77.9B
$161K 0.04%
439
+218
+99% +$78.5K
BBIO icon
452
BridgeBio Pharma
BBIO
$16.5B
$161K 0.04%
2,568
+930
+57% +$53.1K
SPCE icon
453
Virgin Galactic
SPCE
$328M
$160K 0.04%
213
-203
-49% -$115K
PDD icon
454
Pinduoduo
PDD
$121B
$160K 0.04%
1,426
+126
+10% +$16.4K
INVH icon
455
Invitation Homes
INVH
$17.6B
$160K 0.04%
+4,032
New +$143K
EXR icon
456
Extra Space Storage
EXR
$31.3B
$159K 0.04%
926
-93
-9% -$13.9K
LSI
457
DELISTED
Life Storage, Inc.
LSI
$159K 0.04%
+1,414
New +$139K
NSA
458
DELISTED
National Storage Affiliates Trust
NSA
$158K 0.04%
2,994
-376
-11% -$17.2K
NREF
459
NexPoint Real Estate Finance
NREF
$317M
$157K 0.04%
+7,800
New +$160K
KLDO
460
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$157K 0.04%
21,333
HTBK
461
DELISTED
Heritage Commerce
HTBK
$157K 0.04%
+13,855
New +$165K
AUPH icon
462
Aurinia Pharmaceuticals
AUPH
$2B
$157K 0.04%
13,144
+4,404
+50% +$56.1K
ARGX icon
463
argenx
ARGX
$56.3B
$156K 0.04%
508
+71
+16% +$20.2K
ADC icon
464
Agree Realty
ADC
$9.72B
$156K 0.04%
+2,164
New +$152K
SPTS icon
465
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
$6.09B
$156K 0.04%
+5,099
New +$156K
SHV icon
466
iShares 0-1 Year Treasury Bond ETF
SHV
$20.8B
$156K 0.04%
+1,414
New +$156K
SHY icon
467
iShares 1-3 Year Treasury Bond ETF
SHY
$25.4B
$156K 0.04%
1,813
-920
-34% -$79.4K
SPTI icon
468
State Street SPDR Portfolio Intermediate Term Treasury ETF
SPTI
$10.5B
$156K 0.04%
+4,804
New +$155K
IEI icon
469
iShares 3-7 Year Treasury Bond ETF
IEI
$18.1B
$156K 0.04%
1,193
-1,778
-60% -$232K
FR icon
470
First Industrial Realty Trust
FR
$8.81B
$156K 0.04%
2,900
-75
-3% -$3.77K
TRNO icon
471
Terreno Realty
TRNO
$7.68B
$155K 0.04%
2,344
+28
+1% +$1.78K
ANGO icon
472
AngioDynamics
ANGO
$570M
$155K 0.04%
5,656
-3,472
-38% -$84.8K
PSA icon
473
Public Storage
PSA
$60.4B
$155K 0.04%
499
-46
-8% -$12.9K
SUI icon
474
Sun Communities
SUI
$15B
$154K 0.03%
858
-23
-3% -$3.81K
BWA icon
475
BorgWarner
BWA
$12.9B
$153K 0.03%
+3,662
New +$161K

Similar funds

Exane Derivatives's Q2 2021 Portfolio in Review

As of Q2 2021, Exane Derivatives held 1,099 positions worth $441M, up 26% from $350M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Exane Derivatives deployed $74.5M of net new capital in Q2 2021, opening 222 new positions and adding to 266 existing holdings. Its largest new stake was Alcon: 109,041 shares worth $7.62M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 11% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was iShares MSCI Taiwan ETF, an estimated $8.02M trimmed.

  • Exane Derivatives's largest Q2 2021 buy was Alcon: 109,041 shares worth $7.62M.
  • Exane Derivatives added most to UBS Group in Q2 2021, an estimated $15.4M increase.
  • Exane Derivatives's biggest Q2 2021 reduction was iShares MSCI Taiwan ETF, cutting an estimated $8.02M.
  • Exane Derivatives fully exited Deutsche Bank in Q2 2021, selling an estimated $4.27M.
  • Exane Derivatives's ten largest holdings make up 24% of its $441M portfolio in Q2 2021.
  • Exane Derivatives opened 222 new positions and closed 55 in Q2 2021.
  • Exane Derivatives's portfolio value rose 26% quarter-over-quarter to $441M.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.